Novo Nordisk concludes private placement into ZymoGenetics

Bagsvaerd, Denmark - Novo Nordisk A/S (NYSE:NVO) has on Friday, 10 November concluded the transaction it announced on October 23 re a USD 150 million private placement into ZymoGenetics Inc from an international investor consortium led by E M Warburg, Pincus & Co, LLC.

 

Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of enzymes for industrial use. Headquartered in Denmark, Novo Nordisk employs approximately 16,200 people in 68 countries and markets its products in 179 countries. Its B shares are listed on the stock exchanges in Copenhagen and London. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO". A demerger of Novo Nordisk with the intention to spin off the Enzyme Business into a separately listed company is expected to take place following an extraordinary general meeting in mid-November. For further company information, visit Novo Nordisk on the World Wide Web at http://www.novo.dk

 

Media

 

Outside North America: 
Karsten Madsen 
Tel (direct): (+45) 4442 4137

 

In North America 
Susan Toth Jackson 
Tel: (+1) 212-867-0123

 

Investors

 

Outside North America:
Peter Haahr
Tel (direct): (+45) 4442 1207
  
Rasmus Holm-Jørgensen
Tel (direct): (+45) 4442 2983

 

In North America
Rasmus Holm-Jørgensen
Tel (direct): (+1) 212-878 9607